Hepatitis C management: The challenge of dropout associated with male sex and injection drug use

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 1, 2011, Pages 32-40

  Lowry, Damien J ^a   Ryan, John D ^a   Ullah, Naeem ^a   Kelleher, Thomas Barry ^a   Crowe, John ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

audit; compliance; disease management; dropout; hepatitis C; hepatitis C virus; service review

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; DRUG DEPENDENCE; FOLLOW UP; GENOTYPE; HEALTH CARE DELIVERY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTPATIENT CARE; PATIENT ATTITUDE; PATIENT REFERRAL; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE; TREND STUDY;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; PATIENT DROPOUTS; RETROSPECTIVE STUDIES; SEX FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 78650788324     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283414122     Document Type: Article

References (45)

1. Shiffman ML. Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation. Liver Transpl 2003; 9:S14-S20.
2. Chen SL, Morgan TR. The natural history of hepatitis c virus (HCV) infection. Int J Med Sci 2006; 3:47-52. [Epub 2006 Apr 1].
3. Marcellin P. The clinical spectrum of disease. In the Proceedings from the EASL International Consensus Conference on Hepatitis C in Paris. February 26-27, 1999: Volume 1
4. World Health Organisation in collaboration with the Viral Hepatitis Prevention Board. Global surveillance and control of hepatitis C. J Viral Hepat 1999; 6:35-47.
5. Hepatitis C Virus Projections Working Group. Estimates and projections of the hepatitis C virus epidemic in Australia 2006. Canberra: Hepatitis C Sub-Committee, Ministerial Advisory Committee on AIDS, Sexual Health and Hepatitis, 2006. Available at: Http://www.nchecr.unsw.edu.au/ NCHECRweb.nsf/resources/HCVPWG2006/$file/ HCVPWGRepAug06.pdf. Accessed 11 January 2010.
6. Wasley A, Grytdal S, Gallagher K. Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 2008; 57:1-24.
7. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: A review of the available evidence. Clin Infect Dis 2009; 49:561-573.
8. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Eng J Med 2001; 345:215-217.
9. Hepatitis C strategy for England. Department of Health 2002.
10. National Hepatitis C Prevention Strategy. A comprehensive strategy for the prevention and control of hepatitis C virus infection and its consequences. Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention. 2001.
11. Scottish Intercollegiate Guidelines Network. Management of hepatitis C: A national clinical guideline. 2006. ISBN (10) 1 905813 02 3. Available at www.sign.ac.uk.
12. National Hepatitis C Strategy 2005-2008. Commonwealth of Australia 2005. ISBN: 0 642 82656 0.
13. Tait JM, McLeod S, Dillon J. Can we find the missing hepatitis C patients? Gut: An International Journal of Gastroenterology and Hepatology. Abstract for the British Society of Gastroenterology Annual General Meeting 23-26 March 2009.
14. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, et al. Overcoming barriers to prevention, care and treatment of hepatitis C in illicit drugs users. Clin Infect Dis 2005; 40:S276-S285.
15. Fireman M, Indest DW, Blackwell A, Whitehead AJ, Hauser P. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): The importance of routine mental health screening as a component of comanagement model of care. Clin Infect Dis 2005; 40:S286-S291.
16. Cournot M, Glibert A, Castel F, Druart F, Imani K, Lauwers-Cances V, Morin T. Management of hepatitis C in active drug users: Experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004; 28:533-539.
17. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavarin in psychiatric risk groups. Hepatology 2003; 37:443-451.
18. Kresina TF, Khalsa J, Cesari H, Francis H. Hepatitis C virus infection and substance abuse: Medical management and developing models of integrated care-an introduction. Clin Infect Dis 2005; 40:S259-S262.
19. Sulkowski MS, Thomas DL. Epidemiology and natural history of hepatitis C virus infection in injection drug users: Implications for treatment. Clin Infect Dis 2005; 40:S263-S269.
20. Schackman BR, Teixeira PA,Weitzman G, Mushlin AI, Jacobson IM. Qualityof- life tradeoffs for hepatitis C treatment: Do patients and providers agree? Med Decis Making 2008; 28:233-242.
21. Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, et al. Hepatitis C treatment in 'difficult-to-treat' psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology 2007; 46:991-998.
22. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120-124.
23. Kraus MR, Schafer A, Csef H, Faller H, Mork H, Scheurlen M. Compliance with therapy in patients with chronic hepatitis C: Associations with psychiatric symptoms, interpersonal problems and mode of acquisition. Dig Dis Sci 2001; 46:2060-2065.
24. Neri S, Bruno CM, Abate G, Ierna D, Mauceri B, Cilio D, et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 2002; 24:1627-1635.
25. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intreavenous drug abuse. Am J Gastroenterol 2003; 98:2281-2288.
26. Robaeys G, Van Vlierberghe H, Mathei C, Van Ranst M, Bruckers L, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006; 18:159-166.
27. Seal KH, Currie SL, Shen H, Anand BS, Bini EJ, Brau N, et al. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: Does a history of injection drug use matter? J Clin Gastroenterol 2007; 41:199-205.
28. Sergio N, Salvatore T, Gaetano B, Davide P, Claudio I, Massimo L, et al. Immune responses in addicts with hepatitis C treated with interferon and ribavarin. J Gastroenterol Hepatol 2007; 22:74-79.
29. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavarin compared with interferon alfa-2b plus ribavarin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
30. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavarin for chronic hepatitis C virus invection. N Eng J Med 2002; 347:975-982.
31. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankal M, et al. Treatment of acuter hepatitis C with interferon alfa-2b. N Eng J Med 2001; 345:1452-1457.
32. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel-Monaim A, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: A randomised trial. Hepatology 2006; 43:923-931.
33. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavarin combination therapy in chronic hepatitis C: A randomised study of treatment duration and ribavarin dose. Ann Intern Med 2004; 140:346-355.
34. Wiegand J, Buggish P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study. Hepatology 2006; 43:250-256.
35. Foster GR, Goldin RD, Main J, Murray-Lyon I, Hargreaves S, Thomas HC. Management of chronic hepatitis C: Clinical audit of biopsy based management algorithm. Br Med J 1997; 315:453-458.
36. Central Statistics Office. Census 2006: Volume 5 - Ethnic or Cultural Background (including the Irish Traveller Community). Government Publications: Dublin. Available at: Http://www.cso.ie/census/census2006 results/volume-5/vol- 5-2006-complete.pdf (Accessed June 21 2010).
37. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24:289-293.
38. Irving WL, Smith S, Cater R, Pugh S, Neal KR, Coupland CA, et al. Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens. J Viral Hepat 2006; 13:264-271.
39. Norcross JC, Prochaska JO, DiClemente CC. Changing for good: The revolutionary program that explains six stages of change and teaches you how to free yourself from bad habits. New York:William Morrow & Co; 1994.
40. Miller WR, Rollnick S. Motivational interviewing: Preparing people to change addictive behaviour. London: The Guilford Press; 1991.
41. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005; 29:159-165.
42. John-Baptiste A, Varenbut M, Lingley M, Nedd-Rodrigue T, Teplin D, Tomlinson G, et al. Treatment of hepatitis C infection for current or former substance abusers in a community setting. J Viral Hepat 2009; 16:557-567.
43. Media Release: Minister for Health and Ageing, Australia. February 20, 2006. Available at: Http://www.health.gov.au/internet/ministers/ publishing.nsf/Content/6E130AAD737A22FFCA25711B000E9BB6/ $File/abb019.pdf [Accessed 11 January 2010].
44. Downer SR, Meara JG, DaCosta AC, Sethuraman K. SMS text messaging improves outpatient attendance. Aust Health Rev 2006; 30:389-396.
45. Koshy E, Car J, Majeed A. Effectiveness of mobile-phone short messaging service (SMS) reminders for ophthalmology outpatient appointments: An observational study. BMC Ophthal 2008; 8:9. doi:10.1186/1471- 2415-8-9. (Pubitemid 352000991)